BioMarin Pharmaceutical said it agreed to acquire Prosensa Holding NV, a bet that regulators will approve Prosensa’s lead product candidate for a rare form of muscular dystrophy.
WSJ.com: What's News US, Wall Street Journal
Mon, 11/24/2014 - 4:00am
BioMarin Pharmaceutical said it agreed to acquire Prosensa Holding NV, a bet that regulators will approve Prosensa’s lead product candidate for a rare form of muscular dystrophy.